Use of sacubitril/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study
CONCLUSION: In patients with symptomatic HFrEF treated in primary care, the group in whom Sac/Val was initiated was characterized by a higher NYHA class and lower LVEF compared to patients in whom Sac/Val was not initiated. Sac/Val was well tolerated, with a high proportion completing 1 year of therapy.PMID:38656397 | DOI:10.1007/s00059-024-05248-z
Source: Herz - Category: Cardiology Authors: Uwe Zeymer Robert Groves Stephan Hupfer Source Type: research
More News: Cardiology | Diabetes | Diabetes Mellitus | Diovan | Endocrinology | Germany Health | Heart | Heart Failure | Primary Care | Study